Bio Rad Labs (BIO) Stock News

Bio-Rad Laboratories (NYSE: BIO) reported Q2 2025 financial results with total net sales of $651.6 million, representing a 2.1% increase from Q2 2024. The Life Science segment grew 4.9% to $262.8 million, while Clinical Diagnostics remained flat at $388.8 million.

The company reported GAAP net income of $317.8 million ($11.67 per share), compared to a loss of $(2,165.5) million in Q2 2024, largely due to changes in Sartorius AG investment value. Non-GAAP net income was $71.0 million ($2.61 per share).

Bio-Rad updated its 2025 outlook, projecting non-GAAP currency-neutral revenue growth of 0 to 1.0% and improved operating margin guidance to 12.0-13.0%. The company also completed the acquisition of Stilla Technologies, expanding its Droplet Digital PCR portfolio.

Bio-Rad Laboratories (NYSE: BIO) has appointed Rajat Mehta as its new Executive Vice President of Global Commercial Operations, effective August 4, 2025. Mehta, who joins from Labcorp where he served as Senior Vice President, succeeds Mike Crowley, who is retiring after 26 years with Bio-Rad.

Mehta brings significant experience from leadership roles at Labcorp, Thermo Fisher Scientific, and Dow Chemical. He holds an MBA from The Wharton School and a BS in Electrical Engineering from Kurkshetra University. The appointment aims to advance Bio-Rad's long-term strategy in life science research and clinical diagnostics markets.

Bio-Rad Laboratories (NYSE: BIO, BIO.B), a leader in life science research and clinical diagnostics, has scheduled its Q2 2025 earnings release for July 31, 2025, after market close. The company will host a conference call at 2:00 PM Pacific Time (5:00 PM Eastern Time) to discuss the results.

Investors can join via phone using the toll-free number (800) 715-9871 within the U.S. or (646) 307-1963 internationally, with access code 9562470. A live webcast and supplemental earnings presentation will be available on Bio-Rad's investor relations website, with the webcast replay accessible for up to one year.

Bio-Rad Laboratories (NYSE: BIO) has significantly expanded its Droplet Digital PCR (ddPCR) portfolio through two major initiatives: the launch of four new ddPCR platforms and the acquisition of Stilla Technologies. The expansion includes the new QX Continuum™ ddPCR system and the QX700™ series of platforms.

The QX Continuum™ system features four-color multiplexing and up to eight discrete thermal profiles per plate, while the QX700™ series enables seven-color multiplexing and can process over 700 samples per day. Combined with Bio-Rad's existing QX200™ and QX600™ systems, the portfolio now includes over 400,000 assays for life science research and diagnostic applications.

Bio-Rad Laboratories (NYSE: BIO, BIO.B), a leader in life science research and clinical diagnostics products, has announced that Chief Operating Officer Jon DiVincenzo will be available for one-on-one investor meetings at the Jefferies Global Healthcare Conference. The meetings will take place on June 4, 2025 in New York City.

Bio-Rad Laboratories (NYSE: BIO, BIO.B), a leader in life science research and clinical diagnostics, announced that CEO Norman Schwartz and CFO Roop K. Lakkaraju will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference. The event is scheduled for May 21, 2025, at 1:35 PM ET. Investors can access the live webcast and replay through Bio-Rad's Investor Relations website section at bio-rad.com.

Bio-Rad Laboratories reported its Q1 2025 financial results, showing a decline in performance. Total net sales decreased 4.2% to $585.4 million compared to Q1 2024. The Life Science segment saw a 5.4% decline to $228.6 million, while Clinical Diagnostics dropped 3.2% to $356.8 million. GAAP net income fell significantly to $64.0 million ($2.29 per share) from $383.9 million ($13.45 per share) in Q1 2024. However, non-GAAP net income improved to $71.0 million ($2.54 per share) from $65.3 million. Due to market uncertainty, Bio-Rad revised its 2025 outlook, now expecting non-GAAP revenue between -1.0% decline to 1.5% growth, down from previous 1.5-3.5% growth forecast. Operating margin guidance was also reduced to 10.0-12.0% from 13.0-13.5%.

Bio-Rad Laboratories (NYSE: BIO) has announced it will release its first quarter 2025 financial results on Thursday, May 1, 2025, after market close. The company, a global leader in life science research and clinical diagnostics products, will host a conference call at 2:30 PM Pacific Time (5:30 PM Eastern Time) to discuss the results.

Interested participants can join the call by dialing (800) 715-9871 within the U.S. or (646) 307-1963 internationally, using access code: 9562470. A live webcast will be available in the Investor Relations section of Bio-Rad's website, with the replay accessible for up to one year.

Bio-Rad Laboratories (NYSE: BIO) reported Q4 2024 financial results with total net sales of $667.5 million, down 2.0% from Q4 2023. The Life Science segment saw a 5.5% decline to $275.0 million, while Clinical Diagnostics segment increased 0.9% to $392.5 million.

For full-year 2024, revenue decreased 3.9% to $2,566.5 million. The company reported a net loss of $1,844.2 million ($65.36 per share), largely due to changes in fair market value of Sartorius AG investment. Non-GAAP net income was $291.1 million ($10.31 per share).

Bio-Rad announced plans to acquire Stilla Technologies, expecting to close by Q3 2025. The company projects 2025 non-GAAP currency-neutral revenue growth of 1.5-3.5% and operating margin of 13.0-13.5%.